Investigators deployed a survey to assess burnout, stress, emotional wellbeing, and pandemic experiences among pediatric hematology/oncology providers and staff.
Investigators sought to assess outcomes following CD19 CAR T-cell therapy in children and young adults who underwent alloHSCT for B-cell acute lymphoblastic leukemia.
A team of investigators report on their validated nomogram that incorporates pleural effusion into the classification of disease severity in patients with multiple myeloma.
Among patients younger than 49 years, those with actinic keratosis had a nearly 7-times greater likelihood of developing cutaneous squamous cell carcinoma than patients without actinic keratosis.
The accelerated approval was based on data from the multicenter, open-label, phase 2 TROPHY study.
In current urological practice, clinicians decide whether to place a ureteral stent or nephrostomy, but evidence-based treatment guidance is needed.
A team of investigators assessed the frequency and timing of unplanned breast implant removal in patients undergoing with mastectomy, reconstruction, and postmastectomy radiation therapy for locally advanced breast cancer.
A retrospective, single-center crossover study was conducted that compared rates of infection in patients with multiple myeloma during observation compared with those receiving IVIG.
Investigators conducted a study to determine the incidence and clinical course of BK virus hemorrhagic cystitis in children undergoing hematopoietic cell transplantation.
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Researchers sought to determine whether adding ixazomib to treatment with lenalidomide plus dexamethasone would give a benefit to patients with newly diagnosed multiple myeloma.
A team of investigators assessed the application of whole-genome sequencing for genomic profiling of patients with acute myeloid leukemia or myelodysplastic syndromes.
Investigators conducted a phase IIb study to assess the safety and efficacy of umbralisib 800 mg/d in patients with relapsed or refractory non-Hodgkin lymphoma.
Researchers sought to determine whether cambinol would have antitumor activity in multiple myeloma cells.